Latest

Roche fires on all cylinders during virus research

The people of Basel are currently researching intensively on another virus test and a possible medication to treat the disease. Our entry in mid-March (cf. PB v. 16.3.) Came at the right time: Since then the share (CHF 346.90; CH0012032048) has increased by a good 22%.

The sales figures for Q1 presented on Wednesday (April 22) can also convince. Revenues rose 2% year-on-year to CHF 15.1 billion. Because of global business, Roche v. a. currency-adjusted development, in which the Swiss are on track to meet their annual targets at + 7% – Group CEO Severin Schwan (photo) wants to see sales rise by a low to medium single-digit percentage range in 2020 after adjusting for exchange rates. In Q1, Roche benefited from new products that were able to offset the competitive pressure from third-party biosimilars on established drugs. The most important growth drivers were recent developments such as the cancer drug Tecentriq, the hemophilia preparation Hemlibra and the breast cancer fighter Perjeta.

The fight against the corona virus is added to this stable basic business. Roche’s Anti-Sars CoV-2 serology test is in late development and may be available in early May. The monthly production capacity should also be ramped up quickly. The phase III study on the safety and efficacy of Actemra / Roactemra in Covid-19-related pneumonia is also promising. Results should already be available here in early summer. Corona research breathes additional imagination into the paper, which is still not particularly expensive at 18 times earnings and has a nice dividend yield of 2.6%.

Newcomers to PB also join Roche. We are increasing the stop from CHF 233.50 to CHF 265.50.

personal-financial.com

With PLATOW stock exchange to deposit success – test 4 weeks, then 30% discount

PLATOW Börse is the competent advisor for your equity investment. The focus is on the German stock market, supplemented by the best investments from Western Europe and the USA.

This report is not an invitation to buy or sell securities. No liability is assumed for the correctness and completeness of the information or for financial loss.

Tags

Related Articles

Back to top button
Close
Close